AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.24 |
Market Cap | 392.69M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.62 |
PE Ratio (ttm) | -5.23 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3.25 |
Volume | 120,490 |
Avg. Volume (20D) | 460,116 |
Open | 3.30 |
Previous Close | 3.19 |
Day's Range | 3.23 - 3.37 |
52-Week Range | 3.19 - 6.55 |
Beta | undefined |
About OABI
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been geneti...
Analyst Forecast
According to 4 analyst ratings, the average rating for OABI stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 177.35% from the latest price.
Next Earnings Release
Analysts project revenue of $11.27M, reflecting a 133.72% YoY growth and earnings per share of -0.11, making a -21.43% decrease YoY.